Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture

ABSTRACT The risk of cardiovascular events (CVEs) with alendronate use in real‐world hip fracture patients is unknown. This study aimed to investigate the risk of CVE with and without use of alendronate in patients with hip fracture. We conducted a retrospective cohort study using a population‐wide...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral research 2018-08, Vol.33 (8), p.1422-1434
Hauptverfasser:	Sing, Chor‐Wing, Wong, Angel YS, Kiel, Douglas P, Cheung, Elaine YN, Lam, Joanne KY, Cheung, Tommy T, Chan, Esther W, Kung, Annie WC, Wong, Ian CK, Cheung, Ching‐Lung
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Alendronate - adverse effects Alendronate - therapeutic use Alendronic acid ANTIRESORPTIVES Bisphosphonates Cardiovascular diseases Cardiovascular Diseases - chemically induced Cardiovascular Diseases - mortality Cause of Death Cerebral infarction Clinical trials DISEASE AND DISORDERS OF/RELATED TO BONE EPIDEMIOLOGY Female Fractures GENERAL POPULATION STUDIES Health risk assessment Heart attacks Hip Hip Fractures - drug therapy Hip Fractures - mortality Humans Male Mortality Myocardial infarction Osteoporosis - drug therapy Patients Population studies Propensity Score Risk Factors Sensitivity analysis THERAPEUTICS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!